drugset / Trial / NCT05861895
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.
Timeline
- Start
- 2023-12-12
- Primary completion
- 2027-06-23
- Completion
- 2027-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HF158K1 | Unknown | 1.4 g | Intravenous |
| Subject | HF158K1 | Unknown | 2.2 g | Intravenous |
| Subject | HF158K1 | Unknown | 2.9 g | Intravenous |
Indications
No indication recorded.